ISSN Print 2713-2757
ISSN Online 2713-2765
SCIENTIFIC AND PRACTICAL REVIEWED JOURNAL OF FMBA OF RUSSIA
REVIEW
Current trends in anticancer drug prototype in vitro pharmacology: bibliometric analysis 2019–2021
About authors
Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia
Correspondence should be addressed: Pavel V. Ershov
Pogodinskaya, 10, korp 1, Moscow, 119121; ur.xobni@97levap
About paper
Author contribution: Ershov PV — literature search, manuscript writing and formatting, conceptualization of the paper; Makarova AS — literature search, manuscript editing.
Received: 2021-07-21
Accepted: 2021-08-18
Published online: 2021-09-27
|
Fig. 1. Heat map of keyword (MeSH terms and authors' terms) mention frequency in the paper's abstracts
Fig. 2. Distribution of keyword (MeSH terms and authors' terms) co-occurrence based on the bibliographic data analysis
Fig. 3. The distribution of major groups of non-peptide organic compounds as new anticancer drug prototypes
Fig. 4. Heat map of changes in publication activities (2016–2020) on identifying the new anticancer drug prototypes. Note: legend scale — cluster distance; decrease and increase in the number of papers are highlighted in red and blue colors, respectively
Fig. 5. Сitations of papers issued in 2019 and focused on the anticancer drug prototype identification. Original names of compounds are provided Total number of citations for papers issued in 2019
Fig. 6. Associations between the protein targets of anticancer drug prototypes returned by the queries “malignant transformation” and “cancer progression” in the Pathway Studio
Table. Relationship between the biological activity of new anticancer drug prototypes and their molecular targets
Note: PPI — protein-protein interaction; * — approved medications are shown in italics.
